Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Not Yet Recruiting NCT07265752

Tirzepatide for the Treatment of Cannabis Use Disorder

Conditions: Cannabis Use Disorder

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Phase: PHASE2

Enrollment: 6

Sponsor: Brigham and Women's Hospital

Summary

This is a pilot randomized cross-over trial to examine the effects of tirzepatide on cue-reactivity among individuals with cannabis use disorder.

Eligibility Criteria

Inclusion Criteria: * English speaking adults aged 18 and above * Diagnosed with DSM-5 cannabis use disorder, severe Exclusion Criteria: * Active psychosis, active suicidality or homicidality or any psychiatric condition that impair ability to provide informed consent * Any current or lifetime diagnosis of eating disorders including anorexia, bulimia, binge eating or * Comorbid substance use disorder * BMI\

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07265752). StuddyBuddy aggregates publicly available trial information.